Not long ago, Teva Pharmaceuticals was considered a poster child for problematic M&A following the $40 billion acquisition of Allergan’s generics unit Actavis in 2016, which led to Teva cutting a quarter of its workforce in a major restructuring. Now, after almost a decade of cost-cutting and soul-searching, the Israeli drugmaker may have finally turned the page.
Dr. Eric Hughes, CMO, EVP, global R&D, Teva Pharmaceuticals
Permission granted by Teva
Known for more than a century as a generics maker, the company has dabbled in innovative medicines since the approval of the multiple sclerosis treatment Copaxone in the 1990s. Now, new drug development is a priority for Teva, said Dr. Eric Hughes, chief medical officer and executive vice president of global R&D — and a portfolio of marketed products as well as a humming pipeline reflect that mindset change.
“The…